Regeneron (REGN) Remains Strong Buy Following Recent Positive News - Roth Capital
Tweet Send to a Friend
Roth Capital maintains is Buy rating and $362 price target on Regeneron Pharmaceuticals (Nasdaq: REGN) following Monday's slew of news ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
